Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · Real-Time Price · USD
15.40
-0.51 (-3.21%)
Jul 8, 2026, 4:00 PM EDT - Market closed
Lyell Immunopharma Market Cap
Lyell Immunopharma has a market cap or net worth of $359.34 million as of July 8, 2026. Its market cap has increased by 169.93% in one year.
Market Cap
359.34M
Enterprise Value
147.22M
1-Year Change
169.93%
Ranking
Category
Stock Price
$15.40
Market Cap Chart
Since the IPO on June 17, 2021, Lyell Immunopharma's market cap has decreased from $4.13B to $359.34M, a decrease of -91.30%. That is a compound annual growth rate of -38.27%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jul 8, 2026 | 359.34M | -45.04% |
| Dec 31, 2025 | 653.89M | 249.70% |
| Dec 31, 2024 | 186.98M | -61.73% |
| Dec 29, 2023 | 488.63M | -43.52% |
| Dec 30, 2022 | 865.16M | -53.52% |
| Dec 31, 2021 | 1.86B | -54.91% |
| Jun 17, 2021 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| OmniAb | 349.38M |
| Fate Therapeutics | 348.51M |
| Larimar Therapeutics | 343.42M |
| Inhibikase Therapeutics | 337.44M |
| Zentalis Pharmaceuticals | 336.00M |
| Immuneering | 332.54M |
| Lineage Cell Therapeutics | 331.57M |
| Opus Genetics | 331.28M |